- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
- Biological · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 2,286
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A
- Interventions
- rFVIIIFc
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 0 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 17 more
- Conditions
- Ulcerative Colitis
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
- Interventions
- mipomersen sodium
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- ABT-126
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- Long Beach, California • San Francisco, California • Hamden, Connecticut + 6 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema
- Interventions
- SAR447537
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- XTMAB-16
- Drug
- Lead sponsor
- Xentria, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
- Interventions
- Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
- Device
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Wilson Disease
- Interventions
- ALXN1840
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 1 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Tebapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 9
- States / cities
- Lakewood, California • Los Angeles, California • Redlands, California + 6 more
- Conditions
- Crohn Disease
- Interventions
- Etrolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 59
- States / cities
- Arcadia, California • La Jolla, California • Long Beach, California + 51 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 25
- States / cities
- Anniston, Alabama • Burbank, California • La Palma, California + 22 more
- Conditions
- Crohn's Disease
- Interventions
- Filgotinib, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 100
- States / cities
- Dothan, Alabama • Sun City, Arizona • Coronado, California + 80 more
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 29
- States / cities
- Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Interferon β-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Ulcerative Colitis
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
- Conditions
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
- Interventions
- Danicamtiv
- Drug
- Lead sponsor
- Kardigan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
- Interventions
- QLT091001
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Baltimore, Maryland
- Conditions
- Venous Thromboembolism
- Interventions
- Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
- Conditions
- Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
- Interventions
- Placebo Matching Mitapivat, Mitapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
- Interventions
- Camoteskimab, Placebo
- Drug
- Lead sponsor
- Apollo Therapeutics Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more